Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07778810
PHASE2

Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome

Sponsor: Johns Hopkins University

View on ClinicalTrials.gov

Summary

Patients with Sturge-Weber syndrome (SWS) are frequently affected by seizures, and seizures are associated with poorer neurological outcomes. To date there is no established means of predicting or preventing seizure onset. Cannabidiol (Epidiolex) was well tolerated in an open label study in this population. This trial will evaluate whether Epidiolex in presymptomatic Sturge-Weber patients may delay the onset of seizures and improve neurological outcome.

Official title: Epidiolex Pilot Trial for Presymptomatic Treatment of Sturge-Weber Syndrome

Key Details

Gender

All

Age Range

1 Month - 18 Months

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-08

Completion Date

2028-07

Last Updated

2026-08-21

Healthy Volunteers

No

Interventions

DRUG

Epidiolex 100 mg/mL Oral Solution

Epidiolex is a prescription form of cannabidiol used to treat seizures. Epidiolex will be started at 2.5 mg/kg/day divided twice daily. The dose will increase weekly as tolerated over the next 5 weeks to a target dose of 20 mg/kg/day.

Locations (1)

Kennedy Krieger Institute

Baltimore, Maryland, United States